TNFRSF8 and anaplastic large cell lymphoma: In another phase I trial, 18 patients (17 HL and 1 cutaneous ALCL) were treated with a 4-1BB co-stimulated anti-CD30 CAR-T construct, reporting 7 partial responses (46).